Published in J Invest Dermatol on November 01, 2001
Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J (2009) 2.48
Regulation of scar formation by vascular endothelial growth factor. Lab Invest (2008) 1.51
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol (2014) 1.18
Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med (2002) 1.16
Vascular Endothelial Growth Factor and Angiogenesis in the Regulation of Cutaneous Wound Repair. Adv Wound Care (New Rochelle) (2014) 1.11
Novel function for vascular endothelial growth factor receptor-1 on epidermal keratinocytes. Am J Pathol (2005) 1.09
Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis. Vaccine (2004) 0.85
Nano to micro delivery systems: targeting angiogenesis in brain tumors. J Angiogenes Res (2010) 0.82
Nitric oxide effects on the function of aged cells ex vivo and in vivo. In Vivo (2009) 0.76
The Role of Angiogenesis in Cancer Treatment. Biomedicines (2017) 0.75
Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol (1995) 10.61
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med (2001) 7.78
Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol (1998) 3.18
Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med (1995) 2.99
IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol (1992) 2.94
Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol (2001) 2.89
Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. J Clin Invest (2001) 2.78
Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood (1999) 2.65
Monocyte-derived human B-cell growth factor identified as interferon-beta 2 (BSF-2, IL-6). Science (1988) 2.62
Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res (1998) 2.60
Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. EMBO J (2000) 2.44
Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol (1996) 2.42
Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proc Natl Acad Sci U S A (1997) 2.32
Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med (1985) 2.25
Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS (1997) 2.24
Activation of suppressor T cells during Epstein-Barr-virus-induced infectious mononucleosis. N Engl J Med (1979) 2.21
Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood (1996) 2.09
Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. N Engl J Med (1981) 2.05
Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest (2001) 2.04
Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. N Engl J Med (1986) 2.03
Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci U S A (1999) 2.01
Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol (1999) 1.99
Limiting dilution analysis of Epstein-Barr virus-induced immunoglobulin production by human B cells. J Exp Med (1983) 1.97
Human interleukin-10 can directly inhibit T-cell growth. Blood (1993) 1.93
NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med (1993) 1.92
Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood (2001) 1.83
A simple immunomagnetic protocol for the selective isolation and long-term culture of human dermal microvascular endothelial cells. Exp Cell Res (1998) 1.81
Structure, function, and molecular control of the skin lymphatic system. J Investig Dermatol Symp Proc (2000) 1.81
Characteristic T cell dysfunction in patients with chronic active Epstein-Barr virus infection (chronic infectious mononucleosis). J Immunol (1985) 1.76
Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J Virol (1990) 1.74
Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene (2011) 1.67
Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. J Clin Invest (1984) 1.63
Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood (1997) 1.63
Interferon-beta 2/interleukin 6 is a co-stimulant for human T lymphocytes. J Immunol (1988) 1.62
Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med (1998) 1.57
Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol (1995) 1.55
Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci U S A (1996) 1.52
Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. EMBO J (2001) 1.51
B cell differentiation and immunoregulatory T cell function in human cord blood lymphocytes. J Clin Invest (1980) 1.51
Polyclonal immunoglobulin secretion by human B lymphocytes exposed to Epstein-Barr virus in vitro. J Immunol (1979) 1.46
Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas. Am J Pathol (2000) 1.44
Identification of a human VPF/VEGF 3' untranslated region mediating hypoxia-induced mRNA stability. Mol Biol Cell (1998) 1.40
Use of cough swabs in a cystic fibrosis clinic. Arch Dis Child (2001) 1.36
Epstein-Barr virus infection and immunoregulation in man. Adv Immunol (1985) 1.36
Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma. J Invest Dermatol (1999) 1.34
Induction of interleukin-6 during human immunodeficiency virus infection. Blood (1990) 1.32
Relationship between immunoglobulin production and immortalization by Epstein Barr virus. J Immunol (1985) 1.32
Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J Leukoc Biol (1998) 1.32
In vivo detection of human vascular endothelial growth factor promoter activity in transgenic mouse skin. Am J Pathol (2000) 1.31
Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme. J Invest Dermatol (1995) 1.30
Activation of naive and memory T cells by interleukin-15. Blood (1996) 1.29
Murine psoriasis-like disorder induced by naive CD4+ T cells. Nat Med (1997) 1.29
The human interleukin 2 receptor beta chain (p70). Direct identification, partial purification, and patterns of expression on peripheral blood mononuclear cells. J Exp Med (1988) 1.28
IL-10 inhibits apoptotic cell death in human T cells starved of IL-2. Int Immunol (1993) 1.27
Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood (1999) 1.25
A role for deregulated c-Myc expression in apoptosis of Epstein-Barr virus-immortalized B cells. Proc Natl Acad Sci U S A (1994) 1.22
Stimulation of EBV-activated human B cells by monocytes and monocyte products. Role of IFN-beta 2/B cell stimulatory factor 2/IL-6. J Immunol (1988) 1.20
Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice. J Clin Invest (1991) 1.20
Interleukin-10 suppresses human immunodeficiency virus-1 replication in vitro in cells of the monocyte/macrophage lineage. Blood (1994) 1.16
Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood (1999) 1.15
Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders. Blood (2001) 1.15
Interleukin-10 inhibits apoptotic cell death in infectious mononucleosis T cells. J Clin Invest (1994) 1.11
Viral and cellular cytokines in AIDS-related malignant lymphomatous effusions. Blood (2000) 1.10
Infection of human endothelial cells with Epstein-Barr virus. J Exp Med (1995) 1.10
Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells. Oncogene (1997) 1.09
Acute haemorrhagic conjunctivitis during an epidemic outbreak of adenovirus-type-4 injection. Lancet (1975) 1.09
T cell-mediated immunoregulation of Epstein Barr virus- (EBV) induced B lymphocyte activation in EBV-seropositive and EBV-seronegative individuals. J Immunol (1982) 1.08
Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol (2000) 1.06
Contribution of automated hematology analysis to the detection of apoptosis in peripheral blood lymphocytes. Cytometry (2000) 1.05
Ultraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin-1. Br J Dermatol (2005) 1.04
Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol (1993) 1.03
Expression of human herpesvirus-8 oncogene and cytokine homologues in an HIV-seronegative patient with multicentric Castleman's disease and primary effusion lymphoma. Lab Invest (1998) 1.03
Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus. Blood (2001) 1.02
Interleukin-15 promotes angiogenesis in vivo. Biochem Biophys Res Commun (1997) 1.02
B-cell-derived interleukin 1 (IL-1)-like factor. I. Relationship of production of IL-1-like factor to accessory cell function of Epstein-Barr virus-transformed human B-lymphoblast lines. Cell Immunol (1985) 1.02
Regression of experimental Burkitt's lymphoma induced by Epstein-Barr virus-immortalized human B cells. Blood (1994) 1.02
Single trial analysis of neurophysiological correlates of the recognition of complex objects and facial expressions of emotion. Brain Topogr (1999) 1.02
Facial affect recognition in the course of schizophrenia. Eur Arch Psychiatry Clin Neurosci (1996) 1.01
Differential chemokine expression in tissues involved by Hodgkin's disease: direct correlation of eotaxin expression and tissue eosinophilia. Blood (1999) 1.01
Serum viral interleukin-6 in AIDS-related multicentric Castleman disease. Blood (2001) 1.01
A syndrome of peripheral blood T-cell infection with Epstein-Barr virus (EBV) followed by EBV-positive T-cell lymphoma. Blood (1998) 1.00